{"filing":{"accession_number":"0001437749-26-018896","cik":"0001645469","ticker":"MNPR","company_name":"Monopar Therapeutics","form":"8-K","filing_date":"2026-05-29","report_date":null,"primary_document":"mnpr20260529_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926018896/mnpr20260529_8k.htm"},"events":[{"id":8194,"run_id":7187,"accession_number":"0001437749-26-018896","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Monopar disclosed Phase 2 clinical trial results for ALXN1840 (tiomolibdate choline) in Wilson disease patients presented at a major medical conference (EASL 2026). While this represents material clinical progress for a therapeutic candidate, it does not fit neatly into the standard taxonomy categories (not an earnings release, M\u0026A activity, executive change, or financial restatement). Clinical trial results presented at conferences are typically material to investors assessing pipeline value and development progress, warranting classification as other_material.","company_name":"Monopar Therapeutics","ticker":"MNPR","filing_date":"2026-05-29","form":"8-K","submitted_at":null,"items":[{"id":2820,"accession_number":"0001437749-26-018896","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Monopar disclosed Phase 2 clinical trial results for ALXN1840 (tiomolibdate choline) in Wilson disease patients presented at a major medical conference (EASL 2026). While this represents material clinical progress for a therapeutic candidate, it does not fit neatly into the standard taxonomy categories (not an earnings release, M\u0026A activity, executive change, or financial restatement). Clinical trial results presented at conferences are typically material to investors assessing pipeline value and development progress, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:35:30.137733+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2820,"accession_number":"0001437749-26-018896","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Monopar disclosed Phase 2 clinical trial results for ALXN1840 (tiomolibdate choline) in Wilson disease patients presented at a major medical conference (EASL 2026). While this represents material clinical progress for a therapeutic candidate, it does not fit neatly into the standard taxonomy categories (not an earnings release, M\u0026A activity, executive change, or financial restatement). Clinical trial results presented at conferences are typically material to investors assessing pipeline value and development progress, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:35:30.137733+00:00","company_name":"Monopar Therapeutics","ticker":"MNPR","filing_date":"2026-05-29"}]}